We sought to investigate associations between central hemodynamic parameters (estimated from radial pulse wave analyses (PWAs)), cardiovascular disease (CVD), and albuminuria in type 1 diabetes.
Original article
Diabetes is associated with increased arterial stiffness, 1,2 which causes reduced aortic distensibility and amplified peripheral resistance affecting central hemodynamics, cardiac workload, and blood pressure.
Measurements of central hemodynamics can be estimated noninvasively by pulse wave analysis (PWA). The technique entails tonometric recordings of radial pulse waves, visualising the pulse wave characteristics, which are then transformed with a transfer function into central aortic systolic pressure (CASP), central aortic diastolic pressure (CADP), central aortic pulse pressure (CPP), and subendocardial viability ratio (SEVR). 3 CASP represents the ejection pressure by the left ventricle, CADP represents the pressure during cardiac perfusion, and CPP is the product of stroke volume, wave reflection, and arterial stiffness 4 and constitutes a proxy for stiffness of the central arteries. 5 SEVR, previously known as the Buckberg index, is an estimate of myocardial perfusion relative to left ventricular workload, calculated as the ratio between diastolic and systolic pressure-time index. Several studies have shown that central hemodynamics, measured as central blood pressure, are more strongly associated with end-organ damage than brachial blood pressure in the general population. 6, 7 Furthermore, SEVR has been shown to be associated with microalbuminuria in a cross-sectional study of type 1 diabetes patients 8 and to predict cardiovascular disease (CVD) in patients with chronic kidney disease. 9 Recently, we demonstrated 24-hour values of central blood pressure measured with the BPro device (HealthStats, Singapore) to be associated with diabetic complications in our study cohort. 10 In this study, we expand these analyses to the cross-sectional relationship between presence of CVD or albuminuria at baseline and estimates of SEVR and central blood pressure measured in the office with the SphygmoCor device (Atcor Medical, Sydney, Australia). Moreover, we are the first to evaluate the prognostic value for development of end-stage renal disease (ESRD) and all-cause mortality in relation to office measurements of central hemodynamics in patients with type 1 diabetes.
METHODS

Study design and population
The cohort has been previously described. 1 In short, white patients with type 1 diabetes but without ESRD (dialysis, renal transplantation or glomerular filtration rate/estimated GFR (eGFR) < 15 ml/min/1.73m 2 ) attending the outpatient clinic at Steno Diabetes Center were recruited to enter a study investigating central and brachial hemodynamics. In total, 1,285 patients were invited, of which 676 (52.6%) accepted. The study conformed to the Declaration of Helsinki and was approved by the local ethics committee, and all patients gave written informed consent.
Clinical and laboratory methods
Office blood pressure was measured after 15 minutes supine rest as the average of 3 left brachial measurements with appropriate cuff size (UA787; A&D Medical, San Jose, CA). Immediately after blood pressure measurements, electrocardiograph R-wave gated PWA recordings were performed by applanation tonometry with the SphygmoCor device by trained laboratory technicians using the manufacturer's instructions. The SphygmoCor applies an internal general transfer function to calculate measures of arterial stiffness and vascular properties. 3 These measures included aortic pressures (CASP, CADP and CPP) and subendocardial perfusion (SEVR).
Three sequences of pulse waves of 10 seconds were recorded and analyzed, but only readings with an operator index ≥75 were kept, averaged, and used in the analyses. 11 Urinary albumin excretion rate (UAER) was measured in 24-hour sterile urine collections by enzyme immunoassay. Patients were stratified as normoalbuminuric if they, in 2 of 3 consecutive measurements, had UAER <30 mg/24 hour and as albuminuric if UAER was ≥30 mg/24 hour. Patients with a history of elevated UAER, which was subsequently reduced with treatment, were categorized according to historic elevated samples.
All patients had blood samples and phenotypic characteristics collected. Glycated hemoglobin (HbA 1c ) was measured by high-performance liquid chromatography; plasma cholesterol and plasma creatinine concentration were measured by standardized methods. eGFR was calculated by the 4-variable Modification of Diet in Renal Disease. 12 Based on standardized questionnaires, current smoking was defined as ≥1 cigarettes/cigars/pipes per day. CVD was defined as history of revascularization, myocardial infarction, peripheral arterial disease, or stroke. Information on antihypertensive treatment was obtained from questionnaires and cross-checked with medical records at the Steno Diabetes Center.
Ascertainment of events
On 1 July 2013, we ascertained vital status and the incidence of ESRD for all patients through the electronic patient record at Steno Diabetes Center. This record is linked with a nationwide electronic registration of admissions and medical records from hospitalizations and is continuously updated from the Danish Civil Registration System with information on mortality status. ESRD was defined as chronic dialysis, kidney transplantation, or an eGFR/GFR <15 ml/min/1.73m 2 .
Statistical analysis
Normally distributed variables are given as mean ± SD, whereas the non-normally distributed variable (UAER) is given as median (range) and log10 transformed before analysis. Univariable and multivariable linear regression compared measures of central hemodynamics with covariables. Comparisons between groups were performed by unpaired Student t test, analyses of variance, and analyses of covariance. We applied logistic regression to compute standardized odds ratios (ORs) for presence of CVD or albuminuria according to increases in CASP and CPP and decrease in CADP and SEVR.
All adjusted models included sex, age, brachial mean arterial pressure (MAP), heart rate, height, eGFR, HbA 1c , total cholesterol, antihypertensive medication, and smoking. UAER was included in the analyses of the association between hemodynamic parameters and presence of CVD.
Time to the combined endpoint of all-cause mortality or ESRD was analyzed using log-rank test and visualised in a Kaplan-Meier plot. Cox regression analyses adjusted for sex, age, and MAP (because of a low number of events, no further adjustments were made) investigated the risk of the combined endpoint in relation to the 4 hemodynamic variables. A 2-tailed P value <0.05 was considered significant. Statistical analyses were performed using SPSS for Windows version 20.0 (SPSS, Chicago, IL). Table 1 shows baseline characteristics for the analysed cohort. The original cohort consisted of 676 patients, of which 636 (94.1%) had PWA measurements available. Of these, 7 (1.0%) patients had one, 63 (9.3%) had 2, and 565 (83.6%) had 3 measurements with an operator index ≥75 available for analyses. For the hemodynamic variables, correlations between first and second, second and third, and first and third measurements were ≥ 0.99, 0.99, 0.99, and 0.95 for CASP, CADP, CPP, and SEVR, respectively.
RESULTS
Characteristics
In separate adjusted linear regression models that included the 4 hemodynamic measures one at a time, all measures were significantly associated with higher age, diabetes duration, UAER, MAP, and heart rate (P ≤ 0.001). In addition, CASP was associated with female sex, shorter height, and smoking (P ≤ 0.003), CPP was associated with shorter height and smoking (P ≤ 0.02), and SEVR was associated with male sex and higher total cholesterol (P ≤ 0.02). None of the variables were associated with eGFR or HbA 1c after adjustment (P ≥ 0.30). In extended models that also included body mass index and total daily insulin dose, insulin dose was related to all 4 hemodynamic variables (P < 0.001), whereas body mass index was not (P ≥ 0.86).
Hemodynamic parameters and age
Patients were stratified into 8 groups according to age (<40 (n = 81); 40-44 (n = 50); 45-49 (n = 88); 50-54 (n = 94); 55-59 (n = 87); 60-64 (n = 109); 65-69 (n = 72) and >70 (n = 55)), and estimated means (adjusted for sex, MAP, eGFR, UAER, HbA 1c , total cholesterol, heart rate, height, antihypertensive treatment, and smoking) of the hemodynamic parameters were calculated for each group. CASP Heart rate, beats per minute 67 ± 12
Presence of cardiovascular disease, % 21
Normo-, micro-, and macroalbuminuria, % 47, 25, 28
Autonomic dysfunction, % 59
Retinopathy, % 78
Data represents percentage, mean ± SD, or median (range). Autonomic dysfunction was assessed by heart rate variability during deep breathing and classified as present if the value was <11 beats per minute. Retinopathy was classified as present if simplex or proliferative retinopathy or blindness was documented.
Abbreviations: eGFR, estimated glomerular filtration rate; IU, international unit; RAAS, renin angiotensin aldosterone system; UAER, urinary albumin excretion rate. and CPP showed a stepwise increase, whereas CADP and SEVR showed a stepwise decrease according to age groups (P < 0.001 for all) (Figure 1a-d) .
Complications at baseline
Unadjusted analyses. Previous CVD was present in 132 (20.8%) patients. CASP and CPP were higher, whereas CADP and SEVR were lower, in patients with previous CVD vs. those without previous CVD (P ≤ 0.002) ( Table 2) .
In patients with normo-(n = 301), micro-(n = 157), or macroalbuminuria (n = 178), the level of CASP and CPP increased, whereas CADP and SEVR decreased with albuminuria degree (P trend ≤ 0.007) ( Table 2 ). Only SEVR was significantly different between patients with micro-and macroalbuminuria (P = 0.004); thus we combined these 2 groups in further analyses. Figure 2 shows the crude prevalence of CVD and albuminuria (≥30 mg/24 hours) in tertiles of the hemodynamic parameters.
Adjusted analyses. After adjustment CASP and CPP were higher, whereas CADP and SEVR were lower, in patients with CVD vs. those without CVD (adjusted P ≤ 0.005). The adjusted ORs for CVD per 1 SD increase in CASP and CPP were 4.0 (2.2-7.2) and 2.1 (95% confidence interval (CI) = 1.5-2.9), and the adjusted ORs per 1 SD decrease in CADP and SEVR were 3.1 (95% CI = 1.8-5.3) and 1.7 (95% CI = 1.1-2.5), respectively (P ≤ 0.02 for all) ( Table 3) . Additional adjustment for diabetes duration, body mass index, and total daily insulin dose did not alter the results for CASP, CADP, or CPP (P ≤ 0.004). However lower SEVR was no longer associated with CVD (OR = 1.4; 95% CI = 0.9-2.1; P = 0.14).
Albuminuric vs. normoalbuminuric patients had higher CASP and CPP and lower CADP and SEVR (adjusted P ≤ 0.003). The adjusted ORs for albuminuria per 1 SD increase Prevalence of cardiovascular disease (CVD) and albuminuria according to tertiles of hemodynamic variables. There was a stepwise increase in the prevalance of CVD and albuminuria for central aortic systolic pressure (CASP; P = 0.06 and 0.03, respectively) and central aortic pule pressure (CPP; P < 0.001 for both) and a stepwise decrease for central aortic diastolic pressure (CADP; P < 0.001 and P = 0.09) and subendocardial viability ratio (SEVR; P < 0.001 for both). Cutoff values between tertiles were <109, 109-124, and >124 mm Hg for CASP; <34, 34-47, and >47 mm Hg for CPP; <71, 71-78, and >78 mm Hg for CADP; and <133, 133-163, and >163 for SEVR. P values are unadjusted χ 2 . The odds ratios for continuous variables are given for 1 SD increase in all variables, except for central aortic diastolic pressure and subendocardial viability ratio, for which the odds ratios are given for 1 SD decrease. Significant odds ratios are indicated in bold.
Abbreviations: CADP, central aortic diastolic pressure; CASP, central aortic systolic pressure; CPP, central aortic pulse pressure; eGFR, estimated glomerular filtration rate; HbA 1c , glycated hemoglobin; NA, nonapplicable; SEVR, subendocardial viability ratio; UAER, urinary albumin excretion rate. The odds ratios for continuous variables are given for 1 SD increase in all variables, except for central aortic diastolic pressure and subendocardial viability ratio, for which the odds ratios are given for 1 SD decrease. Significant odds ratios are indicated in bold.
Abbreviations: CADP, central aortic diastolic pressure; CASP, central aortic systolic pressure; CPP, central aortic pulse pressure; eGFR, estimated glomerular filtration rate; HbA 1c , glycated hemoglobin; NA, nonapplicable; SEVR, subendocardial viability ratio; UAER, urinary albumin excretion rate.
group.
in CASP and CPP were 4.2 (95% CI = 2.4-7.7) and 2.1 (95% CI = 1.5-2.8), and the adjusted ORs per 1 SD decrease in CADP and SEVR were 2.6 (95% CI = 1.6-4.3) and 2.1 (95% CI = 1.5-3.1), respectively (P < 0.001 for all) ( Table 4) . Additional adjustment for diabetes duration, body mass index, and total daily insulin dose did not alter the results (P ≤ 0.004).
Analyses of albuminuria as a continuous variable showed that all 4 hemodynamic measures (CASP, CPP, CADP, and SEVR) analyzed separately were independently associated with UAER (P ≤ 0.003).
None of the 4 hemodynamic parameters were related to eGFR (P ≥ 0.30). Although patients with low eGFR (<60 ml/ min/1.73m 2 ) had higher CASP and CPP as well as lower SEVR (P ≤ 0.007), but similar CADP (P = 0.54), these associations attenuated after adjustment (P ≥ 0.12).
Follow-up
During follow-up (median (range)) 2.8 (0.7-3.8) years, 18 patients died and 11 developed ESRD. None of the patients who developed ESRD died subsequently during the follow-up period. PWA measurements were available in 16 and 10 of the patients who died or developed ESRD, respectively. Hemodynamic values in patients with event (death or ESRD) vs. those without were 124 ± 20 vs. 118 ± 17 mm Hg (P = 0.07) for CASP; 50 ± 16 vs. 43 ± 14 mm Hg (P = 0.01) for CPP; 75 ± 12 vs. 75 ± 9 mm Hg (P = 0.72) for CADP; and 129 ± 27 vs. 151 ± 32 (P = 0.001) for SEVR. In analyses adjusted for sex, age, and MAP only, SEVR was significantly lower in patients with an event (death or ESRD) (P = 0.005).
Patients with low SEVR (below the mean of 150) had significantly higher event rate (n = 22; 7%) vs. those with high SEVR (n = 4; 1%; P < 0.001) (Figure 3) . In adjusted Cox regression analysis, the hazard ratio for event per 1 SD decrease in SEVR was 2.2 (95% CI = 1.3-3.7; P = 0.002).
Death and ESRD combined was not associated with CASP, CADP, or CPP after adjustment (P ≥ 0.13).
DiSCUSSiOn
We investigated the associations between central hemodynamic parameters and presence of CVD and albuminuria in 636 type 1 diabetes patients. Central hemodynamic measures were CASP, CPP, CADP, and SEVR.
We demonstrated (i) a stepwise increase for CASP and CPP and decrease for both CADP and SEVR with increasing age; (ii) CASP, CPP, CADP, and SEVR were significantly associated with baseline presence of CVD and albuminuria even after adjustment for brachial blood pressure and other conventional risk factors; and (iii) SEVR predicted the combined endpoint of all-cause mortality and ESRD independently of age, sex, and brachial blood pressure during follow-up.
Increasing evidence document the additional value of central blood pressure in prediction of CVD risk. 7, [13] [14] [15] Moreover, an association between CPP and retinal disease was recently reported. 16 We have previously found 24-hour measurements of CASP and CPP obtained with a different device (BPro, HealthStats, Singapore) to be associated with diabetic complications (albuminuria degree, presence of CVD, retinopathy, and autonomic dysfunction) in this cohort. 10 With this study, we found no association between central hemodynamics and retinopathy but a significant association with presence of autonomic neuropathy (heart rate variability during deep breathing; data not shown). Measurements with BPro during 24 hours may provide a more precise estimate of risk, as compared with office blood pressure, whereas office measurements with the SphygmoCor device, which has been tested much more, are faster to perform and provides the ability to estimate SEVR. We have previously shown CASP data with the 2 devices to be strongly correlated. 17 We now show an association between office measurements of central hemodynamics (including CASP, CPP, CADP, and SEVR) and presence of CVD and albuminuria independently of brachial blood pressure, which further ignites the discussion on the potential value of central blood pressure measurements in the management of diabetes patients.
From a pathophysiologic view, it is comprehensible that central hemodynamics may provide superior risk information than brachial blood pressure. Increased CASP and CPP strain the left ventricle, whereas decreased CADP and SEVR compromise cardiac perfusion, thereby impeding the extra workload required by the heart. Conversely, brachial blood pressure results from central pressures and arterial stiffness but only limitedly reflects cardiac function.
Others have shown SEVR to be related to microalbuminuria and reduced kidney function in type 1 diabetes, 8 and a recent study from Italy that included 212 patients with chronic kidney disease mainly without diabetes (28%) followed for a median of 36 months showed that a reduced SEVR significantly predicted cardiovascular mortality. 11 However, we are the first to demonstrate the predictive value of SEVR in patients with type 1 diabetes. Measurements of SEVR are easily obtainable and may prove useful for assessment of cardiac function. It will be interesting to further follow-up our cohort and investigate whether SEVR also predicts CVD. Measurement of central hemodynamics might in the future be implemented in risk assessment. 15 However, whether central hemodynamics provide a worthwhile treatment target is still debated. Some studies have shown different effects of antihypertensive treatment on central and brachial blood pressure. 18, 19 However, recently the X-CELLENT study was unable to show different central and peripheral blood pressure effects by indapamid, candesartan, and amlodipine, 20 as did the CHAMPION trial comparing beta-blockers with different receptor affinities. 21 Thus, some, but not all, antihypertensive medications may exert different effects on central and brachial blood pressure. Another important issue is whether central and brachial blood pressure reductions are equally important for prevention of adverse events. Recently, Kampus et al. showed reduced central blood pressure and ventricular wall thickness when treating with a vasodilating vs. a cardioselective beta-blocker despite similar changes in brachial blood pressure. 22 Thus, it is possible that targeting central blood pressure could become an effective treatment option. The ASCOT trial found a reduced cardiovascular event rate in patients treated with a regimen based on calcium blockers and if needed angiotensin-converting enzyme inhibitors vs. betablockers with diuretics added when needed. 23 The substudy (CAFÉ), which included a segment of 2,199 patients from the original ASCOT cohort, showed a more pronounced blood pressure-reducing effect on central blood pressure in patients receiving calcium blocker-based treatment despite similar effects on brachial blood pressure. Altogether, these data led the authors to infer that the reduced event rate in patients receiving calcium blockers resulted from a larger reduction in central blood pressure. 23 However, trials investigating the superior treatment benefit from targeting central blood pressures rather than peripheral blood pressure are needed.
We and others have previously shown an association between arterial stiffness measured as pulse wave velocity or pulse pressure and diabetic complications, 1, [24] [25] [26] and because increased arterial stiffness affects central hemodynamics, improved treatment could target prevention and reversion of increased arterial stiffness.
Our study has some limitations. Analyses are based on few measurements of central hemodynamics at a single visit. However, the measurements were obtained under uniform conditions by trained laboratory technicians. Patients were not fasting, as is recommended when performing pulse wave analysis. 27 However, because the patients had insulindependent diabetes, fasting was not a safe option for all.
A major strength is the sample size. Being a single-center study, patients were likely receiving similar treatment. Furthermore, the majority of patients had been followed at the Steno Diabetes Center for more than a decade, rendering the information on presence of CVD and albuminuria very reliable. Follow-up data were obtained from the Steno Diabetes Center electronic patient record, which is linked to nationwide electronic databases; thus no patients were lost to follow-up. Number of follow-up events was low, and we were only able to include a limited number of variables in the adjusted model.
In type 1 diabetes patients, central hemodynamic parameters, measured in the office with a well-known method, demonstrated that CASP and CPP showed a stepwise increase, whereas CADP and SEVR showed a stepwise decrease, with higher age, independently of covariables. Also, central hemodynamics were independently associated with presence of CVD and albuminuria. Furthermore, SEVR predicted the combined endpoint of all-cause mortality and ESRD after a median follow-up of 2.8 years.
We demonstrate that central hemodynamics may be important markers of CVD and albuminuria. However, future studies are required to investigate whether central hemodynamics are useful in risk scoring of patients with diabetes and whether targeting central hemodynamics may improve outcome.
